title: [F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients.
abstract: BACKGROUND
  We evaluated the prognostic significance of standardized uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) in [F-18] FDG PET/CT findings in patients with inoperable non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  One hundred and three patients (mean age, 65.6 ± 16 years) underwent [F-18] FDG PET/CT before the chemotherapy. The SUVmax value, the MTV (cm(3); 42% threshold) and the TLG (g) were registered. The patients were followed up to 18 months thereafter (range 12-55 months). Failure to respond without progression, progression and/or disease-related death constituted surrogate end-points. The optimal SUVmax, MTV and TLG cut-off to predict the patients' outcome were estimated. PET/CT results were then related to disease outcome (progression free survival; PFS).
  
  
  RESULTS
  The Kaplan-Meier survival analysis for SUVmax showed a significant shorter PFS in patients presenting with lower values as compared to those with higher (p < 0.05, log-rank test). MTV and TLG were not suitable for predicting PFS apart from the subset of patients with mediastinal nodal involvement.
  
  
  CONCLUSIONS
  Despite the availability of new tools for the quantitative assessment of disease activity on PET/CT, the SUVmax rather than MTV and TLG remains the only predictor for PFS in NSCLC patients. MTV holds a value only when concomitant nodal involvement occurs.
authors.affiliation: Nuclear Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Nappi
authors.affiliation: Nuclear Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
authors.forename: Rosj
authors.initials: R
authors.lastname: Gallicchio
authors.affiliation: Research Laboratories, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Simeon
authors.affiliation: Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Napoli, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Nardelli
authors.affiliation: Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Napoli, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Pelagalli
authors.affiliation: Research Laboratories, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Zupa
authors.affiliation: Research Laboratories, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Vita
authors.affiliation: Nuclear Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Venetucci
authors.affiliation: Università degli Studi di Foggia, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Di Cosola
authors.affiliation: CMO Oplonti Medical Centre, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Barbato
authors.affiliation: Nuclear Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Storto
keywords: Non-small-cell lung cancer; [F-18] FDG PET/CT; glycolytic activity; quantitative assessment; survival
references.citation: Chest. 2000 Feb;117(2):374-9
references.pmid: 10669677
references.citation: Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38
references.pmid: 21946983
references.citation: Chest. 2003 Jan;123(1 Suppl):226S-243S
references.pmid: 12527582
references.citation: Q J Nucl Med Mol Imaging. 2009 Apr;53(2):167-80
references.pmid: 19293765
references.citation: Rep Pract Oncol Radiother. 2013 Jan 05;18(2):76-81
references.pmid: 24416539
references.citation: Eur J Cancer. 2013 Apr;49(6):1374-403
references.pmid: 23485231
references.citation: Nucl Med Commun. 2014 Sep;35(9):908-15
references.pmid: 24785008
references.citation: Clin Lung Cancer. 2012 Jan;13(1):52-8
references.pmid: 21703935
references.citation: Med Oncol. 2014 Jan;31(1):780
references.pmid: 24326983
references.citation: J Cancer Res Clin Oncol. 2010 Jun;136(6):883-9
references.pmid: 19936788
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Clin Invest. 2007 Aug;117(8):2051-8
references.pmid: 17671639
references.citation: Radiol Oncol. 2014 Nov 05;48(4):361-8
references.pmid: 25435849
references.citation: Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1087-94
references.pmid: 20140611
references.citation: Lung Cancer. 2010 Aug;69(2):187-93
references.pmid: 19942313
references.citation: J Thorac Oncol. 2008 Jan;3(1):6-12
references.pmid: 18166834
references.citation: Clin Positron Imaging. 2000 Jul;3(4):182
references.pmid: 11150785
references.citation: J Thorac Oncol. 2009 Sep;4(9):1148-55
references.pmid: 19546818
references.citation: Clin Adv Hematol Oncol. 2013 Oct;11(10):629-39
references.pmid: 24518373
references.citation: Lancet Oncol. 2010 Jan;11(1):75-84
references.pmid: 20129130
references.citation: Clin Lung Cancer. 2011 Sep;12(5):286-92
references.pmid: 21729649
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1285-92
references.pmid: 12663716
references.citation: J Nucl Med. 2006 Mar;47(3):426-31
references.pmid: 16513611
references.citation: Clin Oncol (R Coll Radiol). 2015 Sep;27(9):505-13
references.pmid: 26095646
references.citation: J Clin Oncol. 2015 Oct 20;33(30):3488-515
references.pmid: 26324367
references.citation: Cancer Med. 2015 Sep;4(9):1334-43
references.pmid: 26108458
references.citation: Lung Cancer. 2002 Feb;35(2):179-87
references.pmid: 11804691
references.citation: J Clin Oncol. 2008 Mar 20;26(9):1459-64
references.pmid: 18349396